300238
XSHE
Market cap367mUSD
Nov 20, Last price
8.94CNY
1D
-5.89%
1Q
-25.19%
Jan 2017
-73.19%
IPO
-11.53%
Name
Guanhao Biotech Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Guanhao Biotech Co.,Ltd. is a Chinese enterprise dedicated to the research, production, and marketing of regenerative medicine solutions. Its product portfolio encompasses NormalGEN, a biological dura repair patch crafted from animal tissue, and GrandNeuro, an artificial alternative for dura restoration. For broader surgical applications, the company offers ThormalGEN, another biological surgical patch also derived from animal tissue. DermalGEN, an animal tissue-based wound dressing, is designed for treating burns, scalds, and skin injuries resulting from loss or trauma. Additionally, Guanhao Biotech markets the IREAL breast patch. The company was established in 1999 and is headquartered in Guangzhou, China.
Key people
Xinzhi Wang
Vice Chairman of the Board · since 2024
Finance Director · since 2024
Weikun Zhang
Chief Risk Officer, Deputy General Manager · since 2024
Feng Zhao
General Manager · since 2025
Xianggui Lin
Deputy General Manager · since 2023
Zhen You
Deputy General Manager · since 2023
Junhui Zhao
Executive Deputy General Manager · since 2023
Qingrong Xu
Deputy General Manager, Secretary of the Board · since 2023
Feng Sun
Director · since 2020
Chairman of the Board · since 2025
Chao Deng
Independent Director · since 2023
Junmei Han
Independent Director · since 2020
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||